… of prolonged PCSK9 inhibition induced by antibody action during the lifetime of normal subjects.
… However, we do not know the effect of prolonged PCSK9 inhibition induced by antibody …

… subjects with hypercholesterolemia (LDL-C >85 mg/dL) receiving statin therapy (with or
without ezetimibe) [27]. Subjects … Among 284 subjects with established cardiovascular disease, …

… to subjects with primary hypercholesterolemia on high doses of statin, 15% of subjects had
genetic variants associated with FH and they responded in a similar way to subjects who did …

… The LAPLACE-TIMI 57 trial (NCT01380730) included 631 hypercholesterolemic subjects
who failed to achieve LDL-c levels <85 mg/dl on statins with or without ezetimibe. Participants …

… with and without PCSK9 inhibitors in adults with hypercholesterolemia and reporting clinical
… program for the PCSK9 inhibitor bococizumab (SPIRE [Studies of PCSK9 Inhibition and the …

… our registry; these subjects are most likely statin intolerant patients who would fulfil criteria
for PCSK9 inhibitors anyway. Evidence suggests PCSK9 inhibitors are an excellent treatment …

… Also, in statin-treated subjects, some studies have shown … effect on patients with mixed
hyperlipidemia was not formally … C and ApoB in hypercholesterolemic participants regardless of …

… PCSK9 expression, suggesting a potential limit for LDL-C clearance. PCSK9 inhibitors …
Efficacy data are available for PCSK9 inhibitors in the following settings: patients with HeFH …

… After 36 weeks there were no differences in response to PCSK9-I therapy between
different groups of He-FH subjects. Response to PCSK9-I was significantly lower in carriers of …

… to 64% in healthy subjects and by up to 81% in hypercholesterolemic patients receiving low-
… % in healthy subjects and by up to 61% in patients with hypercholesterolemia receiving 10–…